• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Entrectinib demonstrates prolonged efficacy in an adult case of radiation-refractory fusion glioblastoma.

作者信息

Grogan Patrick T, Deming Dustin A, Helgager Jeffrey, Ruszkiewicz Theresa, Baskaya Mustafa K, Howard Steven P, Robins H Ian

机构信息

Department of Medicine, Division of Hematology, Medical Oncology, and Palliative Care, University of Wisconsin, Madison, Wisconsin, USA.

Department of Pathology and Laboratory Medicine, University of Wisconsin, Madison, Wisconsin, USA.

出版信息

Neurooncol Adv. 2022 Apr 13;4(1):vdac046. doi: 10.1093/noajnl/vdac046. eCollection 2022 Jan-Dec.

DOI:10.1093/noajnl/vdac046
PMID:35673607
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9167633/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bcc8/9167633/5f46fcad391b/vdac046_fig3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bcc8/9167633/ea58f2a400d5/vdac046_fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bcc8/9167633/852772ab4f0d/vdac046_fig2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bcc8/9167633/5f46fcad391b/vdac046_fig3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bcc8/9167633/ea58f2a400d5/vdac046_fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bcc8/9167633/852772ab4f0d/vdac046_fig2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bcc8/9167633/5f46fcad391b/vdac046_fig3.jpg

相似文献

1
Entrectinib demonstrates prolonged efficacy in an adult case of radiation-refractory fusion glioblastoma.恩曲替尼在一例放疗难治性融合型胶质母细胞瘤成年患者中显示出持久疗效。
Neurooncol Adv. 2022 Apr 13;4(1):vdac046. doi: 10.1093/noajnl/vdac046. eCollection 2022 Jan-Dec.
2
Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials.恩曲替尼治疗晚期或转移性 NTRK 融合阳性实体瘤患者的疗效：三项 I/II 期临床试验的整合分析。
Lancet Oncol. 2020 Feb;21(2):271-282. doi: 10.1016/S1470-2045(19)30691-6. Epub 2019 Dec 11.
3
Case Report: A case of complete response to entrectinib in fusion gene-positive parotid gland cancer.病例报告：1例融合基因阳性腮腺癌对恩曲替尼完全缓解的病例
Front Oncol. 2023 Aug 4;13:1247435. doi: 10.3389/fonc.2023.1247435. eCollection 2023.
4
Case report: Acquired neurotrophic tyrosine receptor kinase inhibitor resistance in a patient with pancreatic neuroendocrine carcinoma receiving entrectinib.病例报告：一名接受恩曲替尼治疗的胰腺神经内分泌癌患者获得性神经营养性酪氨酸受体激酶抑制剂耐药
Front Oncol. 2023 Jan 10;12:1031396. doi: 10.3389/fonc.2022.1031396. eCollection 2022.
5
Entrectinib: A New Selective Tyrosine Kinase Inhibitor Approved for the Treatment of Pediatric and Adult Patients with NTRK Fusionpositive, Recurrent or Advanced Solid Tumors.恩曲替尼：一种新型选择性酪氨酸激酶抑制剂，获批用于治疗携带 NTRK 融合的儿童和成年患者的复发性或晚期实体瘤。
Curr Med Chem. 2022;29(15):2602-2616. doi: 10.2174/0929867328666210914121324.
6
Cost-Effectiveness Analysis of Treating Patients With NTRK-Positive Cancer With the Histology-Independent Therapy Entrectinib.治疗 NTRK 阳性癌症患者的成本效益分析，采用组织学独立疗法恩曲替尼。
Value Health. 2023 Feb;26(2):193-203. doi: 10.1016/j.jval.2022.08.006. Epub 2022 Oct 11.
7
Entrectinib for the treatment of metastatic NSCLC: safety and efficacy.恩曲替尼治疗转移性 NSCLC：安全性和疗效。
Expert Rev Anticancer Ther. 2020 May;20(5):333-341. doi: 10.1080/14737140.2020.1747439. Epub 2020 Apr 8.
8
Efficacy and safety exposure-response analyses of entrectinib in patients with advanced or metastatic solid tumors.恩曲替尼治疗晚期或转移性实体瘤患者的疗效和安全性暴露-反应分析。
Cancer Chemother Pharmacol. 2022 Mar;89(3):363-372. doi: 10.1007/s00280-022-04402-w. Epub 2022 Feb 3.
9
Case report: gene fusion in a patient with metastatic lung adenocarcinoma successfully treated with entrectinib.病例报告：一名转移性肺腺癌患者的基因融合通过恩曲替尼成功治疗。
Front Oncol. 2022 Nov 7;12:1038774. doi: 10.3389/fonc.2022.1038774. eCollection 2022.
10
Evolving role of entrectinib in treatment of -positive tumors.恩曲替尼在治疗阳性肿瘤中的作用演变。
Future Oncol. 2021 Aug;17(22):2835-2846. doi: 10.2217/fon-2020-0936. Epub 2021 Apr 26.

引用本文的文献

1
Loss of CARM1 alters the developmental programming of Glioma stem-like cells and creates a druggable NGFR/NTRK dependency.CARM1的缺失改变了胶质瘤干细胞样细胞的发育程序，并产生了一种可靶向治疗的NGFR/NTRK依赖性。
bioRxiv. 2025 Apr 17:2025.04.11.647869. doi: 10.1101/2025.04.11.647869.
2
Evolution of Molecular Biomarkers and Precision Molecular Therapeutic Strategies in Glioblastoma.胶质母细胞瘤中分子生物标志物的演变与精准分子治疗策略
Cancers (Basel). 2024 Oct 29;16(21):3635. doi: 10.3390/cancers16213635.
3
Overcoming Resistance to Temozolomide in Glioblastoma: A Scoping Review of Preclinical and Clinical Data.

本文引用的文献

1
Efficacy and safety of larotrectinib in TRK fusion-positive primary central nervous system tumors.拉罗替尼在TRK融合阳性原发性中枢神经系统肿瘤中的疗效与安全性。
Neuro Oncol. 2022 Jun 1;24(6):997-1007. doi: 10.1093/neuonc/noab274.
2
Discovery of a rare fusion in a pediatric low-grade glioma, leading to targeted treatment with TRK-inhibitor larotrectinib.发现一种罕见融合基因存在于儿童低级别胶质瘤中，可使用 TRK 抑制剂 larotrectinib 进行靶向治疗。
Cancer Biol Ther. 2021 Mar 4;22(3):184-195. doi: 10.1080/15384047.2021.1899573. Epub 2021 Apr 5.
3
The experience of successful treatment of -positive infant glioblastoma with entrectinib.
克服胶质母细胞瘤对替莫唑胺的耐药性：临床前和临床数据的范围综述
Life (Basel). 2024 May 24;14(6):673. doi: 10.3390/life14060673.
4
A novel methylation signature predicts extreme long-term survival in glioblastoma.一种新型甲基化特征可预测胶质母细胞瘤的极长生存期。
J Neurooncol. 2024 Sep;169(2):341-347. doi: 10.1007/s11060-024-04741-z. Epub 2024 Jun 19.
5
Glioblastoma microenvironment-from biology to therapy.胶质母细胞瘤微环境——从生物学到治疗。
Genes Dev. 2024 Jun 25;38(9-10):360-379. doi: 10.1101/gad.351427.123.
6
RNA fusion transcript panel identifies diverse repertoire of fusions in adult glioma patients with therapeutic implications.RNA融合转录本检测 panel 可识别成年胶质瘤患者中具有治疗意义的多种融合类型。
Neurooncol Pract. 2023 Apr 24;10(4):370-380. doi: 10.1093/nop/npad022. eCollection 2023 Aug.
7
NTRK Gene Fusions in Solid Tumors and TRK Inhibitors: A Systematic Review of Case Reports and Case Series.实体瘤中的NTRK基因融合与TRK抑制剂：病例报告和病例系列的系统评价
J Pers Med. 2022 Nov 2;12(11):1819. doi: 10.3390/jpm12111819.
8
Implementing targeted therapies in the treatment of glioblastoma: Previous shortcomings, future promises, and a multimodal strategy recommendation.胶质母细胞瘤治疗中靶向治疗的实施：既往不足、未来前景及多模式策略推荐
Neurooncol Adv. 2022 Sep 28;4(1):vdac157. doi: 10.1093/noajnl/vdac157. eCollection 2022 Jan-Dec.
恩曲替尼成功治疗阳性婴儿胶质母细胞瘤的经验。
Neurooncol Adv. 2021 Feb 3;3(1):vdab022. doi: 10.1093/noajnl/vdab022. eCollection 2021 Jan-Dec.
4
Regression of Infantile Glioblastoma After First-Line Treatment With Larotrectinib.一线使用拉罗替尼治疗后小儿胶质母细胞瘤的消退
JCO Precis Oncol. 2020 Jun 30;4. doi: 10.1200/PO.20.00017. eCollection 2020.
5
Molecular and clinicopathologic features of gliomas harboring NTRK fusions.携带有 NTRK 融合的神经胶质瘤的分子及临床病理特征。
Acta Neuropathol Commun. 2020 Jul 14;8(1):107. doi: 10.1186/s40478-020-00980-z.
6
Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials.恩曲替尼治疗晚期或转移性 NTRK 融合阳性实体瘤患者的疗效：三项 I/II 期临床试验的整合分析。
Lancet Oncol. 2020 Feb;21(2):271-282. doi: 10.1016/S1470-2045(19)30691-6. Epub 2019 Dec 11.
7
Resistance to TRK inhibition mediated by convergent MAPK pathway activation.由汇聚的 MAPK 通路激活介导的 TRK 抑制抗性。
Nat Med. 2019 Sep;25(9):1422-1427. doi: 10.1038/s41591-019-0542-z. Epub 2019 Aug 12.
8
fusion in a low-grade glioma with distinctive morphology and unexpected aggressive behavior.低级别胶质瘤中的融合，具有独特形态和意外侵袭性行为。
Cold Spring Harb Mol Case Stud. 2019 Apr 1;5(2). doi: 10.1101/mcs.a003855. Print 2019 Apr.
9
Buparlisib in Patients With Recurrent Glioblastoma Harboring Phosphatidylinositol 3-Kinase Pathway Activation: An Open-Label, Multicenter, Multi-Arm, Phase II Trial.Buparlisib 治疗携带磷酸肌醇 3-激酶通路激活的复发性胶质母细胞瘤患者的开放性、多中心、多臂、二期临床试验
J Clin Oncol. 2019 Mar 20;37(9):741-750. doi: 10.1200/JCO.18.01207. Epub 2019 Feb 4.
10
NTRK fusion-positive cancers and TRK inhibitor therapy.NTRK 融合阳性癌症和 TRK 抑制剂治疗。
Nat Rev Clin Oncol. 2018 Dec;15(12):731-747. doi: 10.1038/s41571-018-0113-0.